61 Risk factors: a systematic review 2 38. Domenech C, Suciu S, De Moerloose B, et al: Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 99:1220-7, 2014 39. Eipel O, Hegyi M, Csordas K, et al: Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL. Journal of Pediatric Hematology Oncology 38:334-340, 2016 40. Eipel OT, Nemeth K, Torok D, et al: The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy. Int J Hematol 97:216-22, 2013 41. Harris JC, Carel CA, Rosenberg LA, et al: Intermittent high dose corticosteroid treatment in childhood cancer: behavioral and emotional consequences. J Am Acad Child Psychiatry 25:120-4, 1986 42. Hough R, Rowntree C, Goulden N, et al: Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol 172:439-51, 2016 43. Igarashi S, Manabe A, Ohara A, et al: No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children’s Cancer Study Group L95-14 protocol. Journal of Clinical Oncology 23:64896498, 2005 44. Kaymak Cihan M, Karabulut HG, Yurur Kutlay N, et al: Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment. Turk J Haematol 34:151-158, 2017 45. Marino S, Verzegnassi F, Tamaro P, et al: Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer 53:984-91, 2009 46. Mitchell CD, Richards SM, Kinsey SE, et al: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129:734-45, 2005 47. Yetgin S, Tuncer MA, Cetin M, et al: Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 17:328-33, 2003 48. Drigan R, Spirito A, Gelber RD: Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol 20:13-21, 1992 49. Messina CA, Freides D, Faraj BA, et al: The Behavioral Correlates of Increased Platelet Monoamine Oxidase in Children. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 2:11, 1989 50. Eiser C, Eiser JR, Mayhew AG, et al: Parenting the premature infant: balancing vulnerability and quality of life. J Child Psychol Psychiatry 46:1169-77, 2005 51. Eiser C, Davies H, Jenney M, et al: HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 46:35-9, 2006 52. Pound CM, Clark C, Ni A, et al: Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia; a multicentered trial. J Pediatr Hematol Oncol 34:517-23, 2012 53. Warris LT, van den Akker EL, Aarsen FK, et al: Predicting the neurobehavioral side effects of dexamethasone in pediatric acute lymphoblastic leukemia. Psychoneuroendocrinology 72:190-5, 2016 54. Rogers VE, Zhu S, Ancoli-Israel S, et al: Impairment in circadian activity rhythms occurs during dexamethasone therapy in children with leukemia. Pediatr Blood Cancer 61:1986-91, 2014
RkJQdWJsaXNoZXIy MTk4NDMw